Daniel DeAngelo, MD, PhD Discusses Acute Myeloid Leukemia

Daniel DeAngelo, MD, PhD

At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Rare Disease Report sat down with Daniel DeAngelo, MD, PhD of the Dana Farber Cancer Institute to discuss acute myeloid leukemia (AML), his two studies evaluating both elderly and relapsed/refractory patients, and the potential treatment option GMI-1271.

Among the questions asked were:
For more from ASCO, check out our Conference Coverage page.
Printer Printing...